Fibromyalgia (FM) is a prevalent syndrome, characterised by chronic widespread pain, fatigue and impaired sleep. Those that suffer from FM also have to contend with the fact that it is an “invisible disease” and not immediately apparent to others. FM can be debilitating and will often have a significant impact to the quality of life. It also continues to be challenging to diagnose and difficult to treat.
A study recently published in Pain (June 18, 2019) reported an altered microbiome composition in individuals with fibromyalgia. There were differences in the serum levels of butyrate and propionate in patients with FM compared to those without FM.
The promising news is that the study was the “first demonstration of gut microbiome alteration in non-visceral pain”, which is an observation that is likely to pave the way for further studies. The hope is that future studies will foster the exploration of new treatment modalities and offer some hope to FM patients.
Wishing you wellness,